Division of Stroke & Vascular Neurology, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut.
The University of Pennsylvania, Philadelphia.
JAMA Neurol. 2023 Nov 1;80(11):1155-1165. doi: 10.1001/jamaneurol.2023.3240.
Published data about the impact of poststroke seizures (PSSs) on the outcomes of patients with stroke are inconsistent and have not been systematically evaluated, to the authors' knowledge.
To investigate outcomes in people with PSS compared with people without PSS.
MEDLINE, Embase, PsycInfo, Cochrane, LILACS, LIPECS, and Web of Science, with years searched from 1951 to January 30, 2023.
Observational studies that reported PSS outcomes.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist was used for abstracting data, and the Joanna Briggs Institute tool was used for risk-of-bias assessment. Data were reported as odds ratio (OR) and standardized mean difference (SMD) with a 95% CI using a random-effects meta-analysis. Publication bias was assessed using funnel plots and the Egger test. Outlier and meta-regression analyses were performed to explore the source of heterogeneity. Data were analyzed from November 2022 to January 2023.
Measured outcomes were mortality, poor functional outcome (modified Rankin scale [mRS] score 3-6), disability (mean mRS score), recurrent stroke, and dementia at patient follow-up.
The search yielded 71 eligible articles, including 20 110 patients with PSS and 1 166 085 patients without PSS. Of the participants with PSS, 1967 (9.8%) had early seizures, and 10 605 (52.7%) had late seizures. The risk of bias was high in 5 studies (7.0%), moderate in 35 (49.3%), and low in 31 (43.7%). PSSs were associated with mortality risk (OR, 2.1; 95% CI, 1.8-2.4), poor functional outcome (OR, 2.2; 95% CI, 1.8-2.8), greater disability (SMD, 0.6; 95% CI, 0.4-0.7), and increased dementia risk (OR, 3.1; 95% CI, 1.3-7.7) compared with patients without PSS. In subgroup analyses, early seizures but not late seizures were associated with mortality (OR, 2.4; 95% CI, 1.9-2.9 vs OR, 1.2; 95% CI, 0.8-2.0) and both ischemic and hemorrhagic stroke subtypes were associated with mortality (OR, 2.2; 95% CI, 1.8-2.7 vs OR, 1.4; 95% CI, 1.0-1.8). In addition, early and late seizures (OR, 2.4; 95% CI, 1.6-3.4 vs OR, 2.7; 95% CI, 1.8-4.1) and stroke subtypes were associated with poor outcomes (OR, 2.6; 95% CI, 1.9-3.7 vs OR, 1.9; 95% CI, 1.0-3.6).
Results of this systematic review and meta-analysis suggest that PSSs were associated with significantly increased mortality and severe disability in patients with history of stroke. Unraveling these associations is a high clinical and research priority. Trials of interventions to prevent seizures may be warranted.
据作者所知,已有研究关于卒中后癫痫发作(PSS)对卒中患者结局的影响结果并不一致,且尚未进行系统评估。
调查 PSS 患者与无 PSS 患者的结局。
MEDLINE、Embase、PsycInfo、Cochrane、LILACS、LIPECS 和 Web of Science,检索年限为 1951 年至 2023 年 1 月 30 日。
报道 PSS 结局的观察性研究。
使用系统评价和荟萃分析的 Preferred Reporting Items 清单提取数据,使用 Joanna Briggs 研究所工具进行偏倚风险评估。使用随机效应荟萃分析,以比值比(OR)和标准化均数差(SMD)及其 95%置信区间报告数据。使用漏斗图和 Egger 检验评估发表偏倚。进行异常值和元回归分析以探索异质性的来源。数据分析于 2022 年 11 月至 2023 年 1 月进行。
测量结局为死亡率、不良功能结局(改良 Rankin 量表[mRS]评分 3-6)、残疾(平均 mRS 评分)、复发性卒中以及患者随访时的痴呆。
搜索结果得到 71 篇符合条件的文章,其中 20110 例 PSS 患者和 116605 例无 PSS 患者。在有 PSS 的患者中,1967 例(9.8%)有早期癫痫发作,10605 例(52.7%)有晚期癫痫发作。5 项研究(7.0%)的偏倚风险较高,35 项(49.3%)为中度,31 项(43.7%)为低度。PSS 与死亡率风险(OR,2.1;95%CI,1.8-2.4)、不良功能结局(OR,2.2;95%CI,1.8-2.8)、更高的残疾程度(SMD,0.6;95%CI,0.4-0.7)和痴呆风险增加(OR,3.1;95%CI,1.3-7.7)相关,与无 PSS 的患者相比。在亚组分析中,早期癫痫发作而不是晚期癫痫发作与死亡率相关(OR,2.4;95%CI,1.9-2.9 与 OR,1.2;95%CI,0.8-2.0),且缺血性和出血性卒中亚型均与死亡率相关(OR,2.2;95%CI,1.8-2.7 与 OR,1.4;95%CI,1.0-1.8)。此外,早期和晚期癫痫发作(OR,2.4;95%CI,1.6-3.4 与 OR,2.7;95%CI,1.8-4.1)以及卒中亚型与不良结局相关(OR,2.6;95%CI,1.9-3.7 与 OR,1.9;95%CI,1.0-3.6)。
本系统评价和荟萃分析的结果表明,PSS 与卒中患者的死亡率和严重残疾显著增加相关。阐明这些关联是一项高度的临床和研究重点。可能需要进行预防癫痫发作的干预措施试验。